Seeking Income? These 3 AI Stocks Pay Dividends
But perhaps to the surprise of some, several stocks involved closely in the AI trade – Broadcom AVGO, Vertiv VRT, and NVIDIA NVDA – shell out dividend payments. For those interested in getting paid with some AI exposure, let's take a closer look at each.
Vertiv has continued to see stellar growth thanks to hot demand for its cooling solutions, with EPS climbing 77% on the back of a 26% move higher in sales throughout its latest period. It's enjoyed a nice sales acceleration as a result, as shown below.
Image Source: Zacks Investment Research
Shares currently yield a modest 0.2% annually, lower than that of the S&P 500 and the Zacks Technology sector average. Notably, the EPS outlook for its current fiscal year continues to be bullish, with the $3.59 per share expected up 23% over the last year.
Image Source: Zacks Investment Research
Broadcom has long been recognized as a strong dividend technology player thanks to its rock-solid cash-generating abilities that have regularly allowed it to boost payouts. The company boasts a sizable 12.5% five-year annualized dividend growth rate, with shares currently yielding 1.2% annually.
Below is a chart illustrating dividends/share on a quarterly basis.
Image Source: Zacks Investment Research
The stock also boasts the highly-coveted Zacks Rank #1 (Strong Buy) thanks to a bullish EPS outlook, with analysts moving their expectations higher across the board. Current fiscal year growth rates are hard to ignore, with AVGO expected to see 34% EPS growth on 20% higher sales.
Image Source: Zacks Investment Research
NVIDIA continues to be an investor favorite thanks to its cutting-edge Data Center offerings that have resulted in unprecedented growth, with Data Center sales of $35.6 billion throughout its latest period up 90% year-over-year and 16% sequentially.
The rich demand backdrop has kept the stock at a favorable Zacks Rank #2 (Buy), with analysts continuing to remain bullish. And given the positive reaction to the company's GTC AI conference just last week, it's clear that the company remains a prime selection for the AI frenzy.
Image Source: Zacks Investment Research
NVDA shares currently yield a tiny 0.1% annually. But while the yield remains fractional relative to other dividend-paying stocks, the raw share performance has muted this concern entirely. The company raised the payout by 150% last year in May, though no increases have come since.
Image Source: Zacks Investment Research
Bottom Line
Dividends come with great perks for investors, providing a passive income stream and the ability to maximize returns through dividend reinvestment.
Although all three dividend-paying tech stocks above – Broadcom AVGO, Vertiv VRT, and NVIDIA NVDA – aren't high-yield, the bullish outlook for these companies' AI offerings can't be overlooked by income-focused investors seeking the join the frenzy.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
Broadcom Inc. (AVGO) : Free Stock Analysis Report
Vertiv Holdings Co. (VRT) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
19 minutes ago
- CNBC
Asia markets set to open mixed as investors await key economic data in the region
Asia-Pacific markets are expected to trade mixed as investors await a slate of Chinese economic data later in the day, as well as Japan's second-quarter GDP. Happy Friday from Singapore. Asia markets are set for a mixed open. Australia's S&P/ASX 200 was set to start the day marginally lower with futures tied to the benchmark at 8,838, compared with the index's last close of 8.873.8. Japan's Nikkei 225 was set to open higher, with the futures contract in Chicago at 42,795, while its counterpart in Osaka last traded at 42,770, against the index's last close of 42,649.26. Futures for Hong Kong's Hang Seng index stood at 25,316, pointing to a weaker open compared with the HSI's last close of 25,519.32. South Korean markets were closed for a holiday. — Lee Ying Shan The S&P 500 ticked higher on Thursday to eke out its third record close in a row. The benchmark added 0.03%, closing at 6,468.54. The Nasdaq Composite slipped 0.01%, finishing at 21,710.67. The Dow Jones Industrial Average shed 11.01 points, or 0.02%, and settled at 44,911.26. — Lisa Kailai Han In a Thursday interview with CNBC, economist Marc Sumerlin confirmed that he's in the running to be the next Federal Reserve chair. "I got a call last Wednesday that said there was going to be a list [and] I was going to be on it. That's as much as I know right now," he said. "I'm waiting for more guidance on where we go from here." Sumerlin also voiced his support for a big interest rate cut. The former senior economist under then-President George W. Bush said that a 50 basis-point rate cut "seems like pretty much a no-brainer to me." One basis point equals 0.01%, so a 50 basis-point cut would be half a percentage point. — Jeff Cox, Lisa Kailai Han Equities may have further upside from here, but investors should still be mindful of elevated volatility going forward, according to UBS. "While the VIX index of implied stock volatility has fallen to the lowest level since December last year, market swings could pick up quickly if trade tensions escalate significantly, economic data weakens faster than expected, or if geopolitical risks worsen," the bank wrote in a Wednesday note to clients. "Investors who are already allocated to equities in line with their strategic benchmarks should consider structured strategies with capital preservation features, while those underallocated should prepare to add exposure on potential market dips or consider a disciplined approach to phasing into stocks." UBS added that a "well-diversified portfolio" is suited for helping investors hedge against volatility while also setting them up for future gains. — Lisa Kailai Han
Yahoo
an hour ago
- Yahoo
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.89 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +3.39%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.61 per share when it actually produced a loss of $0.65, delivering a surprise of -6.56%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. MacroGenics, which belongs to the Zacks Medical - Products industry, posted revenues of $22.24 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.73%. This compares to year-ago revenues of $10.8 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. MacroGenics shares have lost about 48.9% since the beginning of the year versus the S&P 500's gain of 10%. What's Next for MacroGenics? While MacroGenics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for MacroGenics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.40 on $26.77 million in revenues for the coming quarter and -$2.04 on $92.12 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Ayr Wellness Inc. (AYRWF), has yet to report results for the quarter ended June 2025. This company is expected to post quarterly loss of $0.29 per share in its upcoming report, which represents a year-over-year change of +14.7%. The consensus EPS estimate for the quarter has been revised 1.9% lower over the last 30 days to the current level. Ayr Wellness Inc.'s revenues are expected to be $111.05 million, down 5.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MacroGenics, Inc. (MGNX) : Free Stock Analysis Report Ayr Wellness Inc. (AYRWF) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
UiPath (PATH) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, UiPath (PATH) closed at $10.73, marking a -2.37% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.03%. Meanwhile, the Dow experienced a drop of 0.03%, and the technology-dominated Nasdaq saw a decrease of 0.01%. Shares of the enterprise automation software developer have depreciated by 11.37% over the course of the past month, underperforming the Computer and Technology sector's gain of 6.37%, and the S&P 500's gain of 3.46%. The investment community will be paying close attention to the earnings performance of UiPath in its upcoming release. The company is slated to reveal its earnings on September 4, 2025. The company is predicted to post an EPS of $0.08, indicating a 100% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $347.82 million, reflecting a 9.98% rise from the equivalent quarter last year. PATH's full-year Zacks Consensus Estimates are calling for earnings of $0.56 per share and revenue of $1.55 billion. These results would represent year-over-year changes of +5.66% and +8.49%, respectively. It is also important to note the recent changes to analyst estimates for UiPath. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. UiPath is holding a Zacks Rank of #3 (Hold) right now. In terms of valuation, UiPath is presently being traded at a Forward P/E ratio of 19.76. This indicates a discount in contrast to its industry's Forward P/E of 29.24. We can additionally observe that PATH currently boasts a PEG ratio of 1.07. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Internet - Software industry had an average PEG ratio of 2.18 as trading concluded yesterday. The Internet - Software industry is part of the Computer and Technology sector. With its current Zacks Industry Rank of 74, this industry ranks in the top 30% of all industries, numbering over 250. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UiPath, Inc. (PATH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
